MedTrace Logo

Establishing Clinical Utility of a New Diagnostic Test for Rheumatology Patients

NCT04266860 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 166

Last updated 2020-09-16

No results posted yet for this study

Summary

This study will collect high-quality randomized controlled data from a nationally representative sample of practicing rheumatologists to determine how they currently manage patients with SLE (systemic lupus erythematosus) and how the results of DxTerity's IFN-1 (interferon type I) test change clinical decision making.

Conditions

Interventions

OTHER

Experimental - Test Results and Education

First, these providers will receive educational materials (e.g. a slide deck, mock test result and one-page fact sheet) meant to mimic what physicians will receive in the real-world market as they learn about the DxTerity test. Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the DxTerity test at the clinically-appropriate point in each case.

Sponsors & Collaborators

  • DxTerity Diagnostics

    collaborator INDUSTRY

  • Qure Healthcare, LLC

    lead INDUSTRY

Principal Investigators

  • John Peabody, MD, PhD · President, QURE Healthcare

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-01
Primary Completion
2012-06-01
Completion
2013-03-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04266860 on ClinicalTrials.gov